Gast ::
| Hauptseite > Publikationsdatenbank > Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience > print |
| Hauptseite > Publikationsdatenbank > Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience > print |
| 001 | 844796 | ||
| 005 | 20210129233111.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-018-3992-5 |2 doi |
| 024 | 7 | _ | |a 0340-6997 |2 ISSN |
| 024 | 7 | _ | |a 1432-105X |2 ISSN |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 024 | 7 | _ | |a pmid:29564490 |2 pmid |
| 024 | 7 | _ | |a WOS:000437733300016 |2 WOS |
| 024 | 7 | _ | |a altmetric:34868649 |2 altmetric |
| 037 | _ | _ | |a FZJ-2018-02172 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ceccon, Garry |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2018 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1531397329_26306 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a PurposeWe present our first clinical experience with O-(2-18F-fluoroethyl)-l-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes.MethodsWe retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33–72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes. Mean and maximum tumour-to-brain ratios (TBRmean, TBRmax) were calculated. The definitive diagnosis (tumour progression or posttherapeutic changes) was confirmed either by histopathology (4 of 12 patients) or on clinical follow-up.ResultsIn all nine patients with confirmed tumour progression, the corresponding FET PET showed increased uptake (TBRmax 3.5 ± 0.6, TBRmean 2.7 ± 0.7). In one of these nine patients, FET PET was consistent with treatment-related changes, whereas standard MRI showed a newly diagnosed contrast-enhancing lesion. In two patients treated solely with TTFields without any other concurrent neurooncological therapy, serial FET PET revealed a decrease in metabolic activity over a follow-up of 6 months or no FET uptake without any signs of tumour progression or residual tumour on conventional MRI.ConclusionFET PET may add valuable information in monitoring therapy in individual patients with high-grade glioma undergoing neurooncological treatment including TTFields. |
| 536 | _ | _ | |a 572 - (Dys-)function and Plasticity (POF3-572) |0 G:(DE-HGF)POF3-572 |c POF3-572 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Lazaridis, Lazaros |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Stoffels, Gabriele |0 P:(DE-Juel1)131627 |b 2 |
| 700 | 1 | _ | |a Rapp, Marion |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Weber, Manuel |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Blau, Tobias |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Lohmann, Phillip |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Kebir, Sied |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Herrmann, Ken |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Fink, Gereon R. |0 P:(DE-Juel1)131720 |b 9 |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 10 |
| 700 | 1 | _ | |a Glas, Martin |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 12 |e Corresponding author |
| 773 | _ | _ | |a 10.1007/s00259-018-3992-5 |0 PERI:(DE-600)2098375-X |n 9 |p 1626 - 1635 |t European journal of nuclear medicine and molecular imaging |v 45 |y 2018 |x 1619-7089 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:844796 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)131627 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)131777 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 12 |6 P:(DE-Juel1)143792 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |2 G:(DE-HGF)POF3-500 |v (Dys-)function and Plasticity |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2015 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|